New Blood Test Shows Promise in Detecting Pancreatic Cancer

Colorectal to Pancreatic: Mainz Biomed Expands Reach in Early Cancer Detection

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular diagnostics company specializing in early cancer detection, continues to gain recognition as a pioneering force in the field. With a strong performance in 2024 and expanding global partnerships, the company is making bold strides in transforming how cancer is diagnosed—starting with colorectal and pancreatic cancers. Last year marked a series of strategic and scientific milestones for Mainz Biomed. A…

New Blood Test Shows Promise in Detecting Pancreatic Cancer

Pancreatic cancer is considered the third deadliest cancer in the US, resulting in more than 50 000 deaths each year, partially because tumors of the pancreas often go undetected until later stages. Although early-stage and localized pancreatic cancer has a much higher survival rate, there are no reliable US Food and Drug Administration–approved screening methods to detect tumors before they spread to the lymph nodes or other organs.